American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 345-348 , September 2007

Anticoagulation for Chronic Atrial Fibrillation in Hemodialysis Patients: Which Fruit From the Decision Tree?

  • Kevin C. Abbott, MD, MPH

      Affiliations

    • Walter Reed Army Medical Center, Washington, DC
    • Corresponding Author InformationAddress correspondence to Kevin C. Abbott, MD, MPH, 6900 Georgia Ave, Nephrology Service, Walter Reed Army Medical Center, Washington, DC 20307.
    • ,
  • Robert T. Neff, MD

      Affiliations

    • Walter Reed Army Medical Center, Washington, DC
    • ,
  • Erin M. Bohen, MD

      Affiliations

    • Walter Reed Army Medical Center, Washington, DC
    • ,
  • Rajeev Narayan, MD

      Affiliations

    • William Beaumont Army Medical Center, Fort Bliss, Texas

References 

  1. Vazquez E, Sancehz-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886–890
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. Arch Intern Med. 1987;147:1561–1564
  3. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implication. Arch Intern Med. 1995;155:469–473
  4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375
  5. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870
  6. Wasse H, Gillen DL, Ball AM, et al. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int. 2003;64:1455–1461
  7. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol. 2002;13:2331–2337
  8. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  9. Abbott KC, Bohen EM, Yuan CM, et al. Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system. Am J Kidney Dis. 2006;47:593–603
  10. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–1444
  11. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int. 1994;45:1477–1483
  12. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13:184–190
  13. Quinn RR, Naimark DMJ, Oliver MJ, et al. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? (A cost-utility analysis). Am J Kidney Dis. 2007;50:421–432
  14. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21:35–39
  15. Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 2003;92:868–871
  16. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433–440
  17. Miller LM, Hopman WM, Garland JS, et al. Cardioprotective medication use in hemodialysis patients. Can J Cardiol. 2006;22:755–760
  18. Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis. 2007;49:801–813

PII: S0272-6386(07)01031-1

doi: 10.1053/j.ajkd.2007.07.004

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 345-348 , September 2007

Article Tools